Novo Nordisk A/S shares plummeted 9% after its experimental heart medicine, ziltivekimab, failed to achieve a statistically significant reduction in major cardiovascular events during trials. This setback impacts the company's drug pipeline.
Novo Nordisk Shares Plunge 9% on Failed Heart Medicine Trial
|1 min read
NVODrug TrialBiopharmaStock DropClinical Trials
